Aimmune Therapeutics Inc (NASDAQ:AIMT) Receives $42.83 Average Price Target from Brokerages

Shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) have received an average rating of “Buy” from the eleven research firms that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $42.83.

A number of equities analysts recently commented on AIMT shares. ValuEngine downgraded Aimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, November 29th. BidaskClub upgraded Aimmune Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, December 6th. Goldman Sachs Group set a $27.00 price objective on Aimmune Therapeutics and gave the stock a “hold” rating in a report on Friday, October 25th. Zacks Investment Research upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. Finally, Stifel Nicolaus upgraded Aimmune Therapeutics to a “positive” rating in a report on Monday, September 16th.

In other news, insider Daniel C. Md Adelman sold 20,000 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $30.04, for a total value of $600,800.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Eric Bjerkholt bought 1,550 shares of the business’s stock in a transaction dated Wednesday, September 18th. The stock was bought at an average cost of $22.57 per share, for a total transaction of $34,983.50. The disclosure for this purchase can be found here. 13.75% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AIMT. Price T Rowe Associates Inc. MD grew its stake in shares of Aimmune Therapeutics by 11.4% in the second quarter. Price T Rowe Associates Inc. MD now owns 5,246,604 shares of the biotechnology company’s stock worth $109,234,000 after acquiring an additional 535,072 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Aimmune Therapeutics during the second quarter valued at $10,835,000. Eventide Asset Management LLC boosted its position in shares of Aimmune Therapeutics by 11.1% during the third quarter. Eventide Asset Management LLC now owns 3,084,000 shares of the biotechnology company’s stock valued at $64,579,000 after buying an additional 309,000 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of Aimmune Therapeutics during the third quarter valued at $5,338,000. Finally, Nuveen Asset Management LLC purchased a new stake in shares of Aimmune Therapeutics during the second quarter valued at $3,969,000. 82.31% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Aimmune Therapeutics stock traded up $0.80 during midday trading on Friday, reaching $31.59. 632,057 shares of the company’s stock traded hands, compared to its average volume of 716,936. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.64 and a current ratio of 4.64. The company has a market cap of $1.89 billion, a PE ratio of -8.61 and a beta of -0.03. The stock has a 50 day moving average of $28.24 and a 200-day moving average of $22.68. Aimmune Therapeutics has a 12 month low of $16.95 and a 12 month high of $32.22.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its earnings results on Wednesday, November 6th. The biotechnology company reported ($1.03) EPS for the quarter, meeting analysts’ consensus estimates of ($1.03). During the same period in the prior year, the company posted ($0.89) EPS. On average, equities analysts anticipate that Aimmune Therapeutics will post -3.97 earnings per share for the current fiscal year.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

Featured Article: How mutual funds make money

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.